![]() However, few studies have explicitly examined the utility of this measure longitudinally. In the past few years the MoCA has emerged as a preferred screening measure of cognitive status in clinical and research settings. Despite being developed as a more sensitive alternative to the MMSE, it is unclear whether the MoCA is similarly prone to these practice effects. Collectively, these studies indicate that repeated exposure to brief screening measures can result in reduced sensitivity to detect cognitive changes, particularly from the first to second test exposure. Similar practice effects have been observed in two subtests of a more comprehensive screening measure, the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS Randolph, 1998) over a test-retest interval of two weeks ( Dong, Thompson, Tan, Lim, Pang & Chen, 2013) although the change in total RBANS score was not significant. These practice effects tend to occur between the first and second testing sessions and are likely due to the small number of items on a screening measure ( Falleti, Maruff, Collie, & Darby, 2006). Previous studies have concluded that screening instruments, such as the MMSE, are also highly prone to practice effects in healthy older adults and in those diagnosed with dementia at short retest intervals of ten minutes to 1.5 weeks ( Galasko, Abramson, Corey-Bloom, & Thal, 1993 Jacqmin-Gadda, Fabrigoule, Commenges, & Dartigues, 1997) and longer retest intervals of three months ( Helkala et al., 2002). Studies have demonstrated the sensitivity of the MoCA to detect cognitive impairment in Parkinson’s disease ( Hoops et al., 2009), cardiovascular disease and stroke ( McLennan, Mathias, Brennan, & Stewart, 2011 Pendlebury, Cuthbertson, Welch, Mehta, & Rothwell, 2010), REM sleep behavior disorder ( Gagnon, Postuma, Joncas, Desjardins, & Latreille, 2010), and brain metastases ( Olson, Chhanabhai, & McKenzie, 2008).Ī recent meta-analysis of practice effects on a range of cognitive tests concluded that practice effects are apparent, particularly in the domains of visual memory, attention, working memory, executive functioning and processing speed, and that greater practice effects are observed for shorter test-retest intervals and tests without alternate forms ( Calamia, Markon & Tranel, 2012). The MoCA has additional utility as a measure of cognitive decline in populations independent of Alzheimer’s disease. ![]() ![]() As a result, the MoCA has been increasingly utilized as an effective screening measure for detecting MCI in both clinical and research settings. Since the publication of the original validation study, other studies have cross-validated the MoCA as a brief measure with substantial sensitivity to MCI and mild Alzheimer’s disease ( Freitas, Simões, Alves, & Santana, 2013 Luis, Keegan, & Mullan, 2009). Developed in 2005, the MoCA was introduced as a more sensitive alternative to the Mini-Mental State Exam (MMSE Folstein, Folstein, & McHugh, 1975) in detecting the presence of mild cognitive impairment (MCI) and mild Alzheimer’s disease (90% and 100% sensitivity, respectively Nasreddine et al., 2005). The Montreal Cognitive Assessment (MoCA) is a brief screening measure to determine cognitive status ( Nasreddine et al., 2005). ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |